Pharming Group (NASDAQ:PHAR) Trading Down 2.6%

Shares of Pharming Group (NASDAQ:PHAR) fell 2.6% during trading on Tuesday . The company traded as low as $7.60 and last traded at $7.60. 1,676 shares were traded during mid-day trading, a decline of 63% from the average session volume of 4,540 shares. The stock had previously closed at $7.80.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, August 1st.

Pharming Group Trading Up 1.4 %

The business’s fifty day moving average is $7.92 and its 200-day moving average is $9.07. The firm has a market cap of $536.54 million, a P/E ratio of -49.44 and a beta of 0.14. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter last year, the business earned $0.02 EPS. Analysts predict that Pharming Group will post -0.15 EPS for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.